1-6 of 6
David Raben
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor

Shilpa Bhatia, Anastacia Griego, Shelby Lennon, Ayman Oweida, Jaspreet Sharma, Christina Rohmer, Nomin Uyanga, Sanjana Bukkapatnam, Benjamin Van Court, David Raben, Christian Young, Lynn Heasley, Sana D. Karam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (9): 2049–2059.
https://doi.org/10.1158/1535-7163.MCT-17-1163
Published: 04 September 2018
View articletitled, Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor
Open the PDF for Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor in another window
Includes: Supplementary data
Journal Articles

Abstract B268: A Phase I Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with intermediate/high risk locally advanced squamous cell carcinoma of the head and neck.

Antonio Jimeno, Thomas Galloway, Lori Wirth, Jill Gilbert, Nabil Saba, Julie Bauman, Dimitrios Colevas, Ranee Mehra, David Raben, Cheng-Jung Lai, Robert Laliberte, Maurizio Voi, Barbara Burtness
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B268.
https://doi.org/10.1158/1535-7163.TARG-13-B268
Published: 01 November 2013
View articletitled, Abstract B268: A Phase I Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with intermediate/high risk locally advanced squamous cell carcinoma of the head and neck.
Journal Articles

Abstract A118: The PARP1 inhibitor olaparib (AZD2281) enhances radiation‐induced DNA damage in BRCA1/BRCA2 wild‐type head and neck squamous cell carcinoma cell lines

Barbara A. Frederick, Ashley Fletcher, David Raben
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A118.
https://doi.org/10.1158/1535-7163.TARG-09-A118
Published: 10 December 2009
View articletitled, Abstract A118: The PARP1 inhibitor olaparib (AZD2281) enhances radiation‐induced DNA damage in BRCA1/BRCA2 wild‐type head and neck squamous cell carcinoma cell lines
Journal Articles

Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma

Erica L. Bradshaw-Pierce, Courtney A. Steinhauer, David Raben, Daniel L. Gustafson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (9): 3006–3017.
https://doi.org/10.1158/1535-7163.MCT-08-0370
Published: 11 September 2008
View articletitled, Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma
Open the PDF for Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma in another window
Includes: Supplementary data
Journal Articles

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma

Barbara A. Frederick, Barbara A. Helfrich, Christopher D. Coldren, Di Zheng, Dan Chan, Paul A. Bunn, Jr., David Raben
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (6): 1683–1691.
https://doi.org/10.1158/1535-7163.MCT-07-0138
Published: 15 June 2007
View articletitled, Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma
Open the PDF for Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma in another window
Journal Articles

Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model

David Raben, Cataldo Bianco, Vincenzo Damiano, Roberto Bianco, Davide Melisi, Chiara Mignogna, Francesco Paolo D'Armiento, Luca Cionini, A. Raffaele Bianco, Giampaolo Tortora, Fortunato Ciardiello, Paul Bunn
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (8): 977–983.
https://doi.org/10.1158/1535-7163.977.3.8
Published: 06 August 2004
View articletitled, Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model
Open the PDF for Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model in another window